Aura Biosciences, Inc.
aurabiosciences.comWhat Do They Do?
Develops bel-sar, a light-activated cancer treatment candidate, for patients with choroidal melanoma, other eye cancers and bladder cancer.
10-K for FY2025, filed Mar 30, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$45.6MView ↗
- ▲ +69% (Loss)
- vs −$27M in Q2 FY2025
-
Aug 11, 2026
Aura refocuses on ocular oncology and reduces its workforce
The plan minimizes resources for the bladder cancer program and cuts the workforce by approximately 20%.
Sources
8-K, filed Aug 11, 2026
On the Effective Date the Company announced its organizational realignment (the “Realignment”) to streamline its operating plan and…View ↗
-
May 4, 2026
Natalie Holles becomes CEO as Elisabet de los Pinos departs
Sources
8-K, filed May 4, 2026
On April 29, 2026, the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s…View ↗
Who Do They Compete With?
Competes with Immunocore, Ideaya Biosciences, Ferring Pharmaceuticals, ImmunityBio, CG Oncology, Johnson & Johnson, UroGen Pharma, Protara Therapeutics, Asieris Pharmaceuticals, and Trya Biosciences
10-K for FY2025, filed Mar 30, 2026Currently we are not aware of any other company that has a drug in clinical development for intervention in early choroidal melanoma, or…View ↗
Loading...
